文献速递血液净化与透析水电解质与酸碱

阿奇霉素使用增加血液透析依赖型肾衰竭患者心源性猝死风险

Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure.
PubMed 文献 · Kidney Int · 2022-06-23

基于美国肾脏数据系统(2007-2017)的两项队列研究显示,在血液透析患者中,与阿莫西林类抗生素相比,阿奇霉素治疗与更高的5日心源性猝死相对和绝对风险相关(加权HR 1.70,95%CI 1.36-2.11;每10万治疗疗程加权风险差25.0,95%CI 15.5-36.5);与左氧氟沙星相比,阿奇霉素与更低的相对和绝对风险相关(加权HR 0.79,95%CI 0.64-0.96;每10万治疗疗程加权风险差-18.9,95%CI -35.5至-3.8)。

要点

  • 血液透析患者中,阿奇霉素较阿莫西林类抗生素增加5日心源性猝死风险(加权HR 1.70)。
  • 阿奇霉素较左氧氟沙星降低5日心源性猝死风险(加权HR 0.79)。
  • 临床选择阿奇霉素、左氧氟沙星或阿莫西林类抗生素时,应权衡抗菌获益与心脏风险。

核心结论

  • 在血液透析依赖型肾衰竭患者中,阿奇霉素较阿莫西林类抗生素增加心源性猝死风险,较左氧氟沙星降低心源性猝死风险。
  • 临床选择阿奇霉素、左氧氟沙星或阿莫西林类抗生素时,应权衡这些药物的相对抗菌获益与潜在心脏风险。

研究设计与样本

  • 利用美国肾脏数据系统(2007-2017)数据开展的两项队列研究。
  • 阿奇霉素对比阿莫西林类抗生素队列纳入282,899例患者、725,431个治疗疗程(阿奇霉素381,306个,阿莫西林类344,125个)。
  • 阿奇霉素对比左氧氟沙星队列纳入245,143例患者、554,557个治疗疗程(阿奇霉素387,382个,左氧氟沙星167,175个)。
  • 主要结局为5日心源性猝死,采用逆概率治疗加权生存模型估计风险比、风险差及95%置信区间。

主要发现

  • 阿奇霉素对比阿莫西林类抗生素:加权HR 1.70(95%CI 1.36-2.11),每10万治疗疗程加权风险差25.0(95%CI 15.5-36.5)。
  • 阿奇霉素对比左氧氟沙星:加权HR 0.79(95%CI 0.64-0.96),每10万治疗疗程加权风险差-18.9(95%CI -35.5至-3.8)。

临床怎么用

  • 临床选择阿奇霉素、左氧氟沙星或阿莫西林类抗生素时,应权衡这些药物的相对抗菌获益与潜在心脏风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Azithromycin is an antibiotic with QT-prolonging potential commonly prescribed to individuals receiving hemodialysis. Hemodialysis patients have a high prevalence of clinical conditions, such as structural heart disease, that can enhance the pro-arrhythmic effects azithromycin, but were excluded from prior investigations evaluating the cardiac safety of azithromycin. Using data from the United States Renal Data System (2007-2017), we conducted two cohort studies to examine the cardiac safety of azithromycin relative to amoxicillin-based antibiotics (amoxicillin, amoxicillin/clavulanic acid) and levofloxacin (a fluoroquinolone antibiotic known to prolong the QT-interval) in the hemodialysis population. The primary outcome was five-day sudden cardiac death. Using inverse probability of treatment weighted survival models, we estimated hazard ratios, risk differences, and 95% confidence intervals. The azithromycin vs. amoxicillin-based antibiotic cohort included 282,899 patients and 725,431 treatment episodes (381,306 azithromycin and 344,125 amoxicillin-based episodes). Azithromycin vs. amoxicillin-based antibiotic treatment was associated with higher relative and absolute risks of sudden cardiac death, weighted hazard ratio of 1.70 (95% Confidence Interval, 1.36 to 2.11) and weighted risk difference per 100,000 treatment episodes of 25.0 (15.5 to 36.5). The azithromycin vs. levofloxacin cohort included 245,143 patients and 554,557 treatment episodes (387,382 azithromycin and 167,175 levofloxacin episodes). Azithromycin vs. levofloxacin treatment was associated with lower relative and absolute risks of sudden cardiac death, weighted hazard ratio of 0.79 (0.64 to 0.96) and weighted risk difference per 100,000 treatment episodes of -18.9 (-35.5 to -3.8). Thus, when selecting among azithromycin, levofloxacin, and amoxicillin-based antibiotics, clinicians should weigh the relative antimicrobial benefits of these drugs against their potential cardiac risks.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Assimon MM, Pun PH, Wang L, et al. Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure. Kidney Int. 2022. PMID: 35752324. doi:10.1016/j.kint.2022.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。